Mostrar el registro sencillo del ítem
dc.contributor.author | Alvaro-Meca, Alejandro | |
dc.contributor.author | Ryan, Pablo | |
dc.contributor.author | Micheloud, Dariela | |
dc.contributor.author | De Miguel, Angel | |
dc.contributor.author | Berenguer, Juan | |
dc.contributor.author | Resino, Salvador | |
dc.date.accessioned | 2020-02-25T09:50:22Z | |
dc.date.available | 2020-02-25T09:50:22Z | |
dc.date.issued | 2018 | |
dc.identifier.citation | Sci Rep. 2018 Aug 14;8(1):12137. | es_ES |
dc.identifier.issn | 2045-2322 | es_ES |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/9143 | |
dc.description.abstract | Chronic infections are a major factor in the development of pulmonary embolism (PE). We aimed to evaluate the trends of PE-related hospitalizations and PE-related deaths in people living with HIV (PLWH) during the era of combination antiretroviral therapy (cART) through a retrospective study in Spain. Data were collected from the Minimum Basic Data Set (MBDS) between 1997 and 2013. The study period was fragmented into four calendar periods (1997-1999, 2000-2003, 2004-2007, and 2008-2013). The rate of PE-related hospitalizations remained stable in PLWH (P = 0.361). HIV-monoinfected patients had a higher incidence than HIV/HCV-coinfected patients during all follow-up [(98.7 (95%CI = 92.2; 105.1); P < 0.001], but PE incidence decreased in HIV-monoinfected patients (P < 0.001) and increased in HIV/HCV-coinfected patients (P < 0.001). Concretely, the rate of PE-related hospitalizations decreased significantly in patients monoinfected with HIV [from 203.6 (95%CI = 175.7; 231.6) events per 100,000 patient-years in 1997-1999 to 74.3 (95%CI = 66.1; 82.3) in 2008-2013; P < 0.001], while patients coinfected with HIV/HCV had a significant increase [from 16.3 (95%CI = 11; 21.6) in 1997-1999 to 53.3 (95%CI = 45.9; 60.6) in 2008-2013; P < 0.001]. The mortality rate of PE-related hospitalizations showed a similar trend as PE incidence. In conclusion, the epidemiological trends of PE in PLWH changed during the cART era, with decreases in incidence and mortality in HIV-monoinfected and increases in both variables in patients coinfected with HIV/HCV. | es_ES |
dc.description.sponsorship | We thank the National Centre for Epidemiology (Institute of Health Carlos III, ISCIII, Spain) for supplying the number of people living with HIV/AIDS in Spain. We also thank the Ministry of Health, Consumption and Social Welfare for providing the records of the Minimum Basic Data Set (MBDS). This work has been supported by a grant from “Instituto de Salud Carlos III” (grant numbers PI14/01094 and PI17/00657 to JB, and PI14CIII/00011 and PI17CIII/00003 to SR). The RD16CIII/0002/0002 and RD16/0025/0017 projects also funded the study as part of the Plan Nacional R + D + I and co-funded by ISCIII- Subdirección General de Evaluación y el Fondo Europeo de Desarrollo Regional (FEDER). JB is supported by the “Programa de Intensificación de la Actividad Investigadora en el Sistema Nacional de Salud (I3SNS)”, Refs INT15/00079 and INT16/00100. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Nature Publishing Group | es_ES |
dc.type.hasVersion | VoR | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject.mesh | Adult | es_ES |
dc.subject.mesh | Anti-Retroviral Agents | es_ES |
dc.subject.mesh | Coinfection | es_ES |
dc.subject.mesh | Drug Therapy, Combination | es_ES |
dc.subject.mesh | Female | es_ES |
dc.subject.mesh | Follow-Up Studies | es_ES |
dc.subject.mesh | HIV Infections | es_ES |
dc.subject.mesh | Hepatitis C, Chronic | es_ES |
dc.subject.mesh | Hospital Mortality | es_ES |
dc.subject.mesh | Hospitalization | es_ES |
dc.subject.mesh | Humans | es_ES |
dc.subject.mesh | Incidence | es_ES |
dc.subject.mesh | Male | es_ES |
dc.subject.mesh | Middle Aged | es_ES |
dc.subject.mesh | Pulmonary Embolism | es_ES |
dc.subject.mesh | Retrospective Studies | es_ES |
dc.subject.mesh | Risk Factors | es_ES |
dc.subject.mesh | Spain | es_ES |
dc.title | Trends in pulmonary embolism in patients infected with HIV during the combination antiretroviral therapy era in Spain: A nationwide population-based study | es_ES |
dc.type | journal article | es_ES |
dc.rights.license | Atribución 4.0 Internacional | * |
dc.identifier.pubmedID | 30108235 | es_ES |
dc.format.volume | 8 | es_ES |
dc.format.number | 1 | es_ES |
dc.format.page | 12137 | es_ES |
dc.identifier.doi | 10.1038/s41598-018-29739-2 | es_ES |
dc.contributor.funder | Instituto de Salud Carlos III | |
dc.contributor.funder | Unión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF) | |
dc.description.peerreviewed | Sí | es_ES |
dc.identifier.e-issn | 2045-2322 | es_ES |
dc.relation.publisherversion | https://doi.org/10.1038/s41598-018-29739-2 | es_ES |
dc.identifier.journal | Scientific reports | es_ES |
dc.repisalud.centro | ISCIII::Centro Nacional de Microbiología | es_ES |
dc.repisalud.institucion | ISCIII | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/PI14/01094 | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/PI17/00657 | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/PI17CIII/00003 | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/PI14CIII/00011 | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/RD16CIII/0002/0002 | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/RD16/0025/0017 | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/INT15/00079 | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/INT16/00100 | es_ES |
dc.rights.accessRights | open access | es_ES |